Companies:
49,811
Total Market Cap:
139341286051154.47
Global Rank
#1409
Country Rank
#26
Market Cap
14.61 B
Price
273.36
Change (%)
5.65%
Volume
450,310
ALTEOGEN's latest marketcap:
14.61 B
As of 07/05/2025, ALTEOGEN's market capitalization has reached $14.61 B. According to our data, ALTEOGEN is the 1409th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 14.61 B |
| Revenue (ttm) | 110.4 M |
| Net Income (ttm) | 90.61 M |
| Shares Out | 53.44 M |
| EPS (ttm) | 1.7 |
| Forward PE | 275.39 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/13/2025 |
Market Cap Chart
Data Updated: 07/05/2025
ALTEOGEN's yearly market capitalization.
ALTEOGEN has seen its market value drop from ₩140.32 B to ₩14.61 B since 2014, representing a total decrease of 89.59% and an annual compound decline rate (CAGR) of 19.36%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | ₩14.61 B | 27.17% | 1409 |
| 12/30/2024 | ₩16.49 T | 221.05% | 1578 |
| 12/28/2023 | ₩5.14 T | 160.78% | 3458 |
| 12/29/2022 | ₩1.97 T | -38.41% | 6311 |
| 12/30/2021 | ₩3.2 T | -36.62% | 5114 |
| 12/30/2020 | ₩5.05 T | 442.81% | 2992 |
| 12/30/2019 | ₩929.69 B | 157.11% | 7802 |
| 12/28/2018 | ₩361.6 B | 29.16% | 11411 |
| 12/28/2017 | ₩279.95 B | 36.78% | 13474 |
| 12/29/2016 | ₩204.68 B | -12.69% | 13549 |
Company Profile
About ALTEOGEN Inc.
ALTEOGEN Inc. is a biotechnology company specializing in the development of innovative biopharmaceuticals, including long-acting biobetters, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars.
Key Product Pipeline
- ALT-P1: A long-acting human growth hormone currently in Phase IIa clinical trials.
- ALT-Q2: A long-acting coagulation factor VII for hemophilia treatment, developed using NexP technology.
- ALT-P7: A targeted therapy for breast and gastric cancer in Phase I clinical trials.
- ALT-Q5: An antibody-drug conjugate (ADC) for ovarian cancer, leveraging NexMab ADC technology.
- ALT-LS2: A subcutaneous formulation of trastuzumab for breast and gastric cancer.
Strategic Alliances
- Kissei Pharmaceutical: Collaboration on ALT-L9, a biosimilar of Eylea (Aflibercept) in Phase 1 trials.
- Cristalia: Partnership for ALT-L2, a biosimilar of Herceptin (Trastuzumab) for breast cancer, now in Phase II trials.
Company Background
Founded in 2008, ALTEOGEN Inc. is headquartered in Daejeon, South Korea, and continues to advance its mission of delivering cutting-edge biopharmaceutical solutions.
Frequently Asked Questions
-
What is ALTEOGEN's (KOSDAQ-196170) current market cap?As of 07/05/2025, ALTEOGEN (including the parent company, if applicable) has an estimated market capitalization of $14.61 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does ALTEOGEN (KOSDAQ-196170) rank globally by market cap?ALTEOGEN global market capitalization ranking is approximately 1409 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.